Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROCK-2L study of belumosudil as second-line therapy for chronic GVHD
jRCTs041260046Phase 2Recruiting
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belumosudil in chronic graft-versus-host disease (cGVHD). Primary endpoint: Overall response rate at Week 24. Started Jun 2026; status: recruiting.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on jRCTs041260046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041260046.